Mark Lappe, Chief Executive Officer at Inhibrx Biosciences, Inc. (INBX), bought 44,000 shares at $15.19 ($671K) on 2024-09-10, disclosed to the SEC on 2024-09-10.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.29 | 26,000 | $398K | 59.2% |
| 2 | $15.21 | 9,500 | $144K | 21.5% |
| 3 | $15.19 | 8,500 | $129K | 19.2% |
| Total | $15.25 avg | 44,000 | $671K | 100% |
| Filing → |
| INBX | BUY | 2024-09-03 | $913K | — | Filing → |
| INBX | BUY | 2024-08-22 | $1.0M | — | Filing → |
| INBX | SELL | 2023-03-01 | $2K | — | Filing → |